Evidence map›Paper›PMID 22525437›Full record

ArticleMolecules (Basel, Switzerland)2012

Synthesis and cytotoxic activity of some novel N-pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide derivatives.

Huaiwei Ding, Zhe Chen, Cunlong Zhang, Tian Xin, Yini Wang, Hongrui Song, Yuyang Jiang, Yuzong Chen, Yongnan Xu, Chunyan Tan

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Huaiwei DingSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China. dinghuaiwei627@163.com
Zhe Chen
Cunlong Zhang
Tian Xin
Yini Wang
Hongrui Song
Yuyang Jiang
Yuzong Chen
Yongnan Xu
Chunyan Tan
Tsinghua University · CNUniversity Town of Shenzhen · CNShenyang Pharmaceutical University · CNNational University of Singapore · SG

Funding

Mechanisms of Alcohol Hangover HeadacheR21AA020305 · NIAAA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LEVY, DAN · 2012 to 2013
$442k
NIAAA NIH HHS R21 AA020305
6 · The paper itself

Abstract

A series of novel compounds bearing imidazo[2,1-b]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound N-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide (5a), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl)piperazin-1-yl)pyridin-3-yl)acetamide (5l), with slightly higher inhibition on VEGFR2 than 5a (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC(50) = 1.4 μM) compared with sorafenib (IC(50) = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC(50) = 22.6 μM).

Indexed as

AcetamidesAntineoplastic AgentsDrug Screening Assays, AntitumorHep G2 CellsHumansProtein Kinase InhibitorsThiazolesVascular Endothelial Growth Factor Receptor-2AcetamidesAntineoplastic AgentsN-pyridinyl-2-(6-phenylimidazo(2,1-b)thiazol-3-yl)acetamideProtein Kinase InhibitorsThiazolesVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID22525437
PMCPMC6268833
OpenAlexW2057321378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.